In addition, our data substantiate the hypothesis that NAFLD-induced liver damage is associated with an abnormal SIRT-PGC-1 signaling; however, all these changes were notably reversed by LMF-HSFx treatment. Here, PPARGC1B is linked to metabolic dysfunction-associated steatotic liver disease.